Disparities in chronic spontaneous urticaria: Eligibility for drug reimbursement associated with clinical outcomes

Disparities in chronic spontaneous urticaria: Eligibility for drug reimbursement associated with clinical outcomes

Background: Chronic spontaneous urticaria (CSU) is an immunologic condition with an estimated prevalence of 0.1%. For CSU that is poorly controlled despite the use of antihistamines, omalizumab is the only treatment approved and recommended by international guidelines. Objective: Our aim was to outl...

Full description

Bibliographic Details
Main Authors: Hugo W.F. Mak, MBBS MRes(Med), Valerie Chiang, MBBS, Elsie T.S. Chan, BNurs, Elaine Lee, MSc, Jackie S.H. Yim, MSc, Dorothy L.Y. Lam, MSc, Philip H. Li, MD, FRCP
Format: Article
Language:English
Published: Elsevier 2024-05-01
Series:Journal of Allergy and Clinical Immunology: Global
Subjects:
Urticaria
chronic urticaria
CSU
health disparities
equity
biologics
Online Access:http://www.sciencedirect.com/science/article/pii/S2772829324000390

Internet

http://www.sciencedirect.com/science/article/pii/S2772829324000390

Similar Items